Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive save search
Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
Published: 2022-12-09 (Crawled : 14:00) - biospace.com/
AMAM 4 | $28.0 0.0% 1.4M
|
Professional, Scientific, and T...
|
| O: 185.44%
H: 288.03%
C: 288.03%
arx788 treatment breast positive cancer her2- her2 metastatic breast cancer
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
CADL | $5.54 7.16% 6.85% 570K
|
|
| O: 26.87%
H: 276.85%
C: 215.27%
can-2409 positive cancer pancreatic trial therapeutics
Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks
Published: 2022-12-08 (Crawled : 12:00) - globenewswire.com
PHVS | $20.87 8.92% 7.39% 51K
|
|
| O: 66.93%
H: 184.96%
C: 173.51%
phvs416 treatment positive study
Phio Pharmaceuticals Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at the AACR Annual Meeting 2022
Published: 2022-04-08 (Crawled : 19:00) - biospace.com/
PHIO | News | $0.8299 29.69% 22.63% 7M
|
Health Technology
|
| O: -2.94%
H: 175.0%
C: 167.05%
ph-894 disease positive ph94
Annovis Bio Announces Positive Phase 2 Data - ANVS401 Improves Cognition in Alzheimer's Disease - Patients' Cognition Improved 3.3 Points on ADAS-Cog11
Published: 2021-05-21 (Crawled : 18:00) - biospace.com/
ANVS | $11.49 14.22% -3.05% 310K
|
Health Technology
|
| O: 39.81%
H: 165.43%
C: 62.56%
disease alzheimer phase 2 positive alzheimer’s alzheimer's disease alzheimer's anvs401
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
JSPR | $22.52 4.31% 3.05% 86K
|
|
| O: 210.62%
H: 153.33%
C: 82.67%
treatment disease trial therapeutics positive
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
Published: 2023-09-25 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.459 -5.36% -6.69% 280K
|
Professional, Scientific, and T...
|
| O: 97.29%
H: 144.27%
C: 94.66%
mc138 ttx-mc138 pre-clinical positive therapeutics results glioblastoma
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138Further Supports TTX-MC138 Application in Brain Cancer
Published: 2023-09-25 (Crawled : 17:00) - biospace.com/
RNAZ | $0.459 -5.36% -6.69% 280K
|
Professional, Scientific, and T...
|
| O: 97.29%
H: 144.27%
C: 94.66%
mc138 ttx-mc138 pre-clinical positive cancer application therapeutics results glioblastoma
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
Published: 2023-12-18 (Crawled : 12:00) - globenewswire.com
IVVD | $2.19 -4.78% -4.55% 1.4M
|
Manufacturing
|
| O: 23.93%
H: 133.17%
C: 77.72%
vyd222 covid-19 positive ongoing trial results
PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Published: 2022-09-28 (Crawled : 11:00) - biospace.com/
PEPG | $11.39 8.12% 6.69% 69K
|
|
| O: 16.92%
H: 111.18%
C: 79.77%
edo51 treatment trial duchenne positive phase 1
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057
Published: 2021-03-01 (Crawled : 12:03) - globenewswire.com
MORF | $28.5 1.82% 1.82% 370K
|
Health Technology
|
| O: 24.45%
H: 106.67%
C: 88.56%
phase 1 positive results trial phase 3 phase 2
NanoVibronix Cites Positive Results from Independent Testing of UroShield
Published: 2023-08-30 (Crawled : 18:00) - biospace.com/
NAOV 4 | $0.7451 -6.86% -5.68% 20K
|
Health Technology
|
| O: 44.83%
H: 101.43%
C: 15.71%
positive results uroshield
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
Published: 2024-03-06 (Crawled : 13:30) - globenewswire.com
NXL | $1.63 13.99% 13.33% 120K
|
|
| O: -1.61%
H: 95.85%
C: 52.0%
device positive technology results study
Reviva Announces Full Details of Positive Phase 2 Clinical Trial Results for Acute Schizophrenia
Published: 2021-04-26 (Crawled : 11:00) - biospace.com/
RVPH | $3.09 2.32% 2.27% 110K
|
|
| O: 14.58%
H: 91.92%
C: 75.76%
phase 2 schizophrenia positive results trial trial results
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma
Published: 2023-12-12 (Crawled : 21:00) - globenewswire.com
CCCC | $6.86 2.08% 2.33% 560K
|
Health Technology
|
| O: 35.9%
H: 89.62%
C: 73.27%
cft7455 positive trial therapeutics
Senseonics Announces a Positive Coverage Decision for Eversense CGM from EmblemHealth
Published: 2021-01-19 (Crawled : 17:00) - biospace.com/
SENS | $0.3988 -0.1% 0.3% 2.1M
|
Electronic Technology
|
| O: 1.27%
H: 86.25%
C: 78.13%
positive
OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel
Published: 2022-12-13 (Crawled : 13:00) - ir.opgen.com
OPGN | $0.598 -5.08% -5.18% 91K
|
Commercial Services
|
| O: 96.32%
H: 84.47%
C: -5.87%
trial positive infection
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
Published: 2024-03-07 (Crawled : 11:00) - globenewswire.com
IMRN | $2.6015 12.62% 4.94% 15K
|
Health Technology
|
| O: 104.23%
H: 76.85%
C: 35.01%
travelan positive trials results
Moleculin Announces Presentation of Positive Pharmacokinetics and Tissue-Organ Distribution Data Demonstrating High Antitumor Activity of Annamycin in Preclinical Cancer Models
Published: 2023-04-18 (Crawled : 18:00) - prnewswire.com
MBRX | $4.3 -7.53% -4.49% 17K
|
Health Technology
|
| O: 1.6%
H: 73.68%
C: -9.79%
distribution presentation positive cancer preclinical
Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)
Published: 2022-06-17 (Crawled : 17:00) - biospace.com/
SRRK 4 | $14.0 1.08% 1.14% 820K
|
Health Technology
|
| O: 4.12%
H: 73.52%
C: 6.52%
extension trial positive muscular atrophy
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
ONFO | $0.6088 38.68% 27.74% 7.3M
|
n/a
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
Your saved searches
Save your searches and get alerts when important news are released.